Cardiac fibrosis, a hallmark of heart failure and various cardiomyopathies, represents a complex pathological process that has long challenged therapeutic intervention. High-throughput omics ...

Bayer and Suzhou Puhe BioPharma Co. Ltd., a clinical-stage biotechnology company, on Wednesday announced that they have entered into a global license agreement for Puhe BioPharma's oral, small ...

Researchers have uncovered a promising therapeutic target for adenoid cystic carcinoma (ACC), a rare cancer of the salivary ...

In the intricate landscape of human biochemistry, few processes wield as much influence over overall health as methylation. This fundamental cellular mechanism, involving the transfer of methyl ...

Bayer BAYRY announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company.Suzhou Puhe BioPharma is focused on the research and development of innovative ...

Tango Therapeutics (TNGX), a biotechnology company with a market capitalization of $190 million, has been making waves in the oncology space with its focus on developing PRMT5 inhibitors for solid ...

Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors Chondrosarcomas are rare cancers of cartilage with limited systemic therapy options. To ...

New protein arginine N-methyltransferase 5 (PRMT5) inhibitors are detailed in a Scinnohub Pharmaceutical Co. Ltd. patent and described as potentially useful for the treatment of cancer.

Pharmaengine Inc. has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

This cover highlights the article Multimodal mechanisms of human centriole engagement and disengagement by Kei K. Ito, Shoji Hata, Daiju Kitagawa and colleagues. The cover image depicts the centriole ...